| (Values in U.S. Thousands) | Mar, 2024 | Dec, 2023 | Sep, 2023 | Jun, 2023 | Mar, 2023 |
| Sales | 7,030 | 30,850 | 10,040 | 8,590 | 9,390 |
| Sales Growth | -77.21% | +207.27% | +16.88% | -8.52% | +237.77% |
| Net Income | -17,920 | 5,960 | -11,720 | -13,160 | -13,270 |
| Net Income Growth | -400.67% | +150.85% | +10.94% | +0.83% | +29.64% |
Alpine Immune Sciences Inc (ALPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based in Seattle, Washington.
Fiscal Year End Date: 12/31